Barclays’s Acurx Pharmaceuticals ACXP Stock Holding History

Barclays’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.41K	Buy	+380	New	+$1.08K	﹤0.01%	4884

Other funds holding ACXP

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

PFS

Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return

Barclays's ACXP Position: Q1 2026 in Review

Barclays opened a new position in Acurx Pharmaceuticals (ACXP) in Q1 2026: 380 shares worth $1.41K. The stake represents ﹤0.01% of the portfolio and ranks #4884 among its holdings.

21 funds tracked by Wall St. Rank hold ACXP as of Q1 2026.

Barclays held 380 shares of Acurx Pharmaceuticals worth $1.41K as of Q1 2026.
Acurx Pharmaceuticals was a new Barclays position in Q1 2026.
Acurx Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4884 holding.
21 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.